News - Alimta

Filter

Current filters:

Alimta

Popular Filters

Lilly's Alimta patent upheld through 2022

Lilly's Alimta patent upheld through 2022

01-04-2014

US pharma major Eli Lilly says that the US District Court for the Southern District of Indiana has ruled…

AlimtaEli LillyLegalNorth AmericaOncologyPatentsPharmaceuticalTeva Pharmaceutical IndustriesUSA

Negative NICE appraisal for Eli Lilly’s Alimta as maintenance therapy

27-02-2014

UK health care guidance body the National Institute for Health and Care Excellence (NICE) has published…

AlimtaEli LillyNorthern EuropeOncologyPharmaceuticalPricingRegulationUK

Third NICE consultation on Eli Lilly’s Alimta in the UK

Third NICE consultation on Eli Lilly’s Alimta in the UK

27-11-2013

The UK’s drugs watchdog the National Institute of Health and Care Excellence (NICE) is holding a third…

AlimtaEli LillyOncologyPharmaceuticalRegulationUK

Eli Lilly exceeds expectations with third quarter results

Eli Lilly exceeds expectations with third quarter results

24-10-2013

US pharma major Eli Lilly has announced financial results for the third quarter of 2013. Despite the…

AlimtaAmyvidAxironCialisCymbaltaEffientEli LillyEvistaFinancialForteoHumalogNorth AmericaPharmaceuticalStratteraTrajentaZyprexa

NICE holds second consultation on Alimta for lung cancer maintenance

20-08-2013

The UK's drugs watchdog the National Institute of Health and Care Excellence (NICE) is holding a second…

AlimtaEli LillyEuropeOncologyPharmaceuticalRegulation

Eli Lilly records higher than expected earnings in 2nd-qtr results

24-07-2013

US drug major Eli Lilly's (NYSE: LLY) recorded higher than expected earnings as growth in key products…

AlimtaCialisCymbaltaEffientEli LillyEvistaFinancialForteoHumalogNorth AmericaPharmaceuticalStratteraZyprexa

Turkey's NSCLC drug market forecast to expand at 7% a year through 2017

13-06-2013

From 2012 to 2017, the non-small-cell lung cancer (NSCLC) market in Turkey will increase at an annual…

AlimtaBiotechnologyEli LillyEuropeMarkets & MarketingOncologyPharmaceuticalRocheTarceva

NICE final draft guidance on Eli Lilly's Alimta negative

13-06-2013

UK drugs watch dog the National Institute for Health and Care Excellence (NICE) this morning (June 13)…

AlimtaEli LillyEuropeOncologyPharmaceuticalPricingRegulation

More highlights from ASCO for: Eisai's Halaven; Boehringer's nintedanib; and Lilly's Alimta

03-06-2013

Among further highlights from the ongoing American Society of Clinical Oncology (ASCO) meeting in Chicago,…

AlimtaBoehringer IngelheimEisaiHalavenLillynintedanibOncologyPharmaceuticalResearch

NICE draft guidance rejects Eli Lilly's Alimta for NSCLC maintenance

22-02-2013

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has issued new draft…

AlimtaEli LillyEuropeOncologyPharmaceuticalPricingRegulation

Nexavar use in Chinese patients nearly doubled in 2012

19-12-2012

Use of Nexavar (sorafenib, from Bayer [BAYN: DE] and Onyx Pharmaceuticals) has nearly doubled in first-line…

AlimtaAsia-PacificBayerBiotechnologyEli LillyMarkets & MarketingNexavarOncologyPharmaceutical

FDA clears new use for Eli Lilly's Alimta

19-10-2012

US drug major Eli Lilly (NYSE: LLY) says that patients may receive Alimta (pemetrexed for injection)…

AlimtaEli LillyNorth AmericaOncologyPharmaceuticalRegulation

Lilly's Alimta combo lung cancer trial fails to meet primary endpoint

07-09-2012

There was disappointing news for US drug major Eli Lilly (NYSE: LLY) yesterday ,as the company announced…

AlimtaAvastinEli LillyOncologyPharmaceuticalResearch

More news from ASCO meeting

05-06-2012

More positive late-stage clinical data continued to roll out at the Annual Meeting of the American Society…

AlimtaBayerdabrafenibEli LillyGlaxoSmithKlineOncologyPharmaceuticalregorafenibResearchtrametinib

Lilly’s Alimta shows benefit in hard-to-treat lung cancer patients

28-09-2011

US drug major Eli Lilly (NYSE: LLY) says that a new subgroup analysis of data from the pivotal Phase…

AlimtaEli LillyOncologyPharmaceuticalResearch

Back to top